United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) - orbifloxacin 30 mg in 1 ml - indications: orbax® oral suspension is indicated for the treatment of urinary tract infections (cystitis) in dogs caused by susceptible strains of staphylococcus pseudintermedius, proteus mirabilis, escherichia coli and enterococcus faecalis . orbax® oral suspension is also indicated for skin and soft tissue infections (wounds and abscesses) in dogs caused by susceptible strains of staphylococcus pseudintermedius, staphylococcus aureus , coagulase positive staphylococci, pasteurella multocida, proteus mirabilis, pseudomonas spp., klebsiella pneumoniae, escherichia coli, enterobacter spp., citrobacter spp., enterococcus faecalis , β-hemolytic streptococci (group g) and streptococcus equisimilis . contraindications: orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. orbifloxacin is contraindicated in immature dogs during the rapid growth phase (between 2 and 8 months of age

Ireland - English - HPRA (Health Products Regulatory Authority)

schering plough limited - orbifloxacin, micronised - oral suspension - 30 mg/ml - canine - antibacterial

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - orbifloxacin (vet.) - oral suspension - 30 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - orbifloxacin, micronised - oral suspension - 30 mg/ml - antibacterial - canine feline

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) - orbifloxacin 22.7 mg - indications: orbax® (orbifloxacin) tablets are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to orbifloxacin. contraindications: orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. orbifloxacin is contraindicated in immature dogs during the rapid growth phase (between 2 and 8 months of age in small and medium-sized breeds, and up to 18 months of age in large and giant breeds). orbifloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - orbifloxacin - oral suspension - antimicrobial - cats, dogs

United States - English - NLM (National Library of Medicine)

katayama seiyakusyo co., ltd. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) -

United States - English - NLM (National Library of Medicine)

sumitomo dainippon pharma co., ltd. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) -

Austria - English - HMA (Heads of Medicines Agencies)

schering-plough limited - orbifloxacin 30 mg/ml - oral suspension - cats, dogs - orbifloxacin

Germany - English - HMA (Heads of Medicines Agencies)

schering-plough limited - orbifloxacin 30 mg/ml - oral suspension - cats, dogs - orbifloxacin